Nurix Therapeutics, Inc.
NRIX
$15.96
-$0.32-1.97%
NASDAQ
| 02/28/2026 | 11/30/2025 | 08/31/2025 | 05/31/2025 | 02/28/2025 | |
|---|---|---|---|---|---|
| Revenue | -66.12% | 2.21% | -37.29% | 264.34% | 11.26% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -66.12% | 2.21% | -37.29% | 264.34% | 11.26% |
| Cost of Revenue | 20.78% | 23.50% | 55.22% | 59.63% | 39.31% |
| Gross Profit | -52.09% | -28.75% | -82.37% | 7.58% | -53.23% |
| SG&A Expenses | 25.36% | 27.35% | 12.30% | 21.96% | -1.23% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 21.43% | 24.03% | 47.74% | 52.36% | 31.57% |
| Operating Income | -47.14% | -28.52% | -67.34% | 0.45% | -39.02% |
| Income Before Tax | -54.70% | -33.62% | -76.82% | 3.94% | -36.02% |
| Income Tax Expenses | -- | -100.00% | -- | 744.44% | -- |
| Earnings from Continuing Operations | -54.70% | -33.60% | -76.53% | 2.43% | -35.73% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -54.70% | -33.60% | -76.53% | 2.43% | -35.73% |
| EBIT | -47.14% | -28.52% | -67.34% | 0.45% | -39.02% |
| EBITDA | -49.22% | -28.65% | -71.13% | 0.28% | -40.16% |
| EPS Basic | -17.44% | -10.16% | -52.65% | 27.43% | 10.82% |
| Normalized Basic EPS | -17.44% | -10.18% | -52.92% | 28.56% | 10.62% |
| EPS Diluted | -17.44% | -10.16% | -52.65% | 27.43% | 10.82% |
| Normalized Diluted EPS | -17.44% | -10.18% | -52.92% | 28.56% | 10.62% |
| Average Basic Shares Outstanding | 31.73% | 21.27% | 15.64% | 34.48% | 52.20% |
| Average Diluted Shares Outstanding | 31.73% | 21.27% | 15.64% | 34.48% | 52.20% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |